BACKGROUND: The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA. PATIENTS AND METHODS: Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [-2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin-based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records. RESULTS: Alpha-blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha-blocker and 5-ARI dual therapy was associated with reduced levels of fPSA, [-2]proPSA, and PHI. Therapy combining alpha-blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin-recognized glycan originating in fPSA. CONCLUSION: BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.

Department of Immunochemistry Diagnostics University Hospital and Faculty of Medicine in Pilsen Charles University Pilsen 323 00 Czech Republic

Department of Pharmacology and Toxicology Faculty of Medicine in Pilsen Charles University Pilsen 323 00 Czech Republic

Glycanostics Ltd Kudlakova 7 Bratislava 841 01 Slovak Republic

Institute of Chemistry Slovak Academy of Sciences Dubravska cesta 9 845 38 Bratislava Slovak Republic

See more in PubMed

Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1(suppl 1):1‐6. PubMed

Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(suppl 9):3. PubMed PMC

Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impotence Res. 2008;20:S11‐S18. PubMed

Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Eur Urol. 1997;31(3):272‐280. PubMed

Roehrborn CG, Schwinn DA. α1‐Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171(3):1029‐1035. PubMed

Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11‐19. PubMed

McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557‐563. PubMed

Roehrborn CG, BRUSKEWITZ R, NICKEL JC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171(3):1194‐1198. PubMed

EAU Guidelines . Edn. presented at the EAU Annual Congress Milan 2023 . 2023, Arnhem, The Netherlands.

Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‐Year results from the CombAT study. Eur Urol. 2010;57(1):123‐131. PubMed

Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843. PubMed PMC

Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987‐1006. PubMed

Ornstein DK, Pruthi RS. Prostate‐specific antigen. Expert Opin Pharmacother. 2000;1(7):1399‐1411. PubMed

Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of prostate cancer screening in Goteborg, Sweden. BMC Med. 2008;6:19. 10.1186/1741-7015-6-19 PubMed DOI PMC

Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046‐1055. PubMed PMC

Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44(5):433‐440. PubMed

Fuchsova R, Topolcan O, Windrichova J, et al. PHI in the early detection of prostate cancer. Anticancer Res. 2015;35(9):4855‐4857. PubMed

Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci. 2019;20(6):1389. PubMed PMC

Butler W, Huang J. Glycosylation changes in prostate cancer progression. Front Oncol. 2021;11:809170. 10.3389/fonc.2021.809170 PubMed DOI PMC

Hatano K, Yoneyama T, Hatakeyama S, et al. Simultaneous analysis of serum α2,3‐linked sialylation and core‐type fucosylation of prostate‐specific antigen for the detection of high‐grade prostate cancer. Br J Cancer. 2022;126(5):764‐770. PubMed PMC

Lang R, Rolny V, Leinenbach A, et al. Investigation on core‐fucosylated prostate‐specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. Tumor Biol. 2019;41(3):1010428319827223. PubMed

Pinkeova A, Kosutova N, Jane E, et al. Medical relevance, state‐of‐the‐art and perspectives of “Sweet Metacode” in liquid biopsy approaches. Diagnostics. 2024;14(7):713. PubMed PMC

Pihikova D, Kasak P, Kubanikova P, Sokol R, Tkac J. Aberrant sialylation of a prostate‐specific antigen: electrochemical label‐free glycoprofiling in prostate cancer serum samples. Anal Chim Acta. 2016;934:72‐79. PubMed PMC

Bruun L, Becker C, Hugosson J, Lilja H, Christensson A. Assessment of intra‐individual variation in prostate‐specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate. 2005;65(3):216‐221. PubMed PMC

Šimánek V, Vrzáková R, Viták R, et al. Preanalytical stability of molecular forms of prostate‐specific antigen in serum samples (PSA, free PSA, [−2]proPSA) and their impact on fPSA/tPSA ratio and PHI. Prostate. 2024;84(7):656‐665. PubMed

Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P. Clarifying the PSA grey zone: the management of patients with a borderline PSA. Int J Clin Pract. 2016;70(11):950‐959. PubMed

Hart J, Spencer B, McDermott CM, et al. A pilot retrospective analysis of alpha‐blockers on recurrence in men with localised prostate cancer treated with radiotherapy. Sci Rep. 2020;10(1):8191. PubMed PMC

Sakalis V, Gkotsi A, Charpidou D, Tsafrakidis P, Apostolidis A. The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate‐specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta‐analysis. Cent European J Urol. 2021;74(3):388‐421. PubMed PMC

Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011;185(1):126‐131. PubMed

Chiu PKF, Chan CH, Liu AQ, et al. A prospective evaluation of the effect of finasteride on prostate health index (phi). Int Urol Nephrol. 2023;55(5):1087‐1092. PubMed

Morote J, Lorente JA, Raventós CX, et al. Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer. Actas Urol Esp. 1998;22(10):835‐839. PubMed

Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate‐specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology. 1997;50(6):901‐905. PubMed

Matzkin H, Barak M, Braf Z. Effect of finasteride on free and total serum prostate‐specific antigen in men with benign prostatic hyperplasia. Br J Urol. 1996;78(3):405‐408. PubMed

Song Y, Chen G, Huang P, Hu C, Liu X. Effects of tamsulosin combined with solifenacin on lower urinary tract symptoms: evidence from a systematic review, Meta‐Analysis, and trial sequential analysis of randomized controlled trials. Front Pharmacol. 2020;11:763. 10.3389/fphar.2020.00763 PubMed DOI PMC

Sakalis V, Sfiggas V, Vouros I, Salpiggidis G, Papathanasiou A, Apostolidis A. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study. Int J Urol. 2018;25(8):737‐745. PubMed

Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci. 2019;20(6):1389. PubMed PMC

Pinkeova A, Tomikova A, Bertokova A, et al. Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study. PLoS One. 2024;19(3):e0300430. PubMed PMC

Ohyama C, Hosono M, Nitta K, et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology. 2004;14(8):671‐679. PubMed